<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00448006</url>
  </required_header>
  <id_info>
    <org_study_id>BIS-CL-001</org_study_id>
    <nct_id>NCT00448006</nct_id>
  </id_info>
  <brief_title>Clinical Feasibility Study of Allium's Biliary Stent</brief_title>
  <official_title>A Clinical Feasibility Study to Evaluate the New Allium Biliary Stent, in Patients Suffering From &quot;Malignant Biliary Duct Obstruction&quot; (Endoscopic Insertion)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allium, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allium, Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of the Allium Biliary Stent
      in malignant obstructions of the common bile duct.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Biliary duct stenoses are caused by intrinsic malignant disease of the common bile duct or by
      compression or infiltration of malignancies of the abdominal organs, i.e. pancreas, liver,
      stomach, duodenum, etc, or by iatrogenic reasons such as endoscopic biliary stone
      manipulations, biliary anastomoses or biliary duct reimplantation. In these diseases, a stent
      can be placed in the biliary duct canal to &quot;open it&quot; and relieve the obstruction. The Allium
      Biliary Stent is to be inserted into the biliary duct to allow free flow of biliary fluid
      from the liver to the duodenum by supporting the obstructed area of the biliary duct lumen,
      keep it open, and prevent its re-obstruction.
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <start_date type="Anticipated">April 2008</start_date>
  <primary_completion_date>August 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Body temperature measurement, patient comfort analysis, sonographic measurements of the duct channels, abdominal X-ray imaging of the stent, and blood tests will be performed at 24 hours, 30 days, 3, 6, and 12 months following stent insertion.</measure>
    <time_frame>up to 12 months follow up</time_frame>
  </primary_outcome>
  <enrollment type="Actual">0</enrollment>
  <condition>Malignant Obstruction of the Common Bile Duct</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Allium Biliary Stent</intervention_name>
    <description>device</description>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>allium biliary stent</intervention_name>
    <description>allium biliary stent</description>
    <other_name>self expandable stent</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient is 18 years or older

          -  Patient has malignant obstructive jaundice

          -  Patient is unfit for surgery

          -  Patient is capable of giving informed consent

          -  Patient is willing to comply with study requirements

        Exclusion Criteria:

          -  Patient has a benign biliary duct obstruction

          -  Patient cannot tolerate any form of antibiotic treatment

          -  Patient is currently receiving anticoagulation therapy

          -  Patient has history of illness, medication, or surgery that may affect the efficacy of
             the stent (e.g.: a previous surgical change in the anatomy of the common bile duct)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Simon Bar-Meir, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sheba Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sheba Medical Center</name>
      <address>
        <city>Ramat Gan</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <link>
    <url>http://eng.sheba.co.il/main/siteNew/index.php</url>
    <description>The Chaim Sheba Medical Center at Tel Hashomer</description>
  </link>
  <verification_date>April 2008</verification_date>
  <study_first_submitted>March 14, 2007</study_first_submitted>
  <study_first_submitted_qc>March 14, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 15, 2007</study_first_posted>
  <last_update_submitted>July 9, 2018</last_update_submitted>
  <last_update_submitted_qc>July 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>common</keyword>
  <keyword>bile</keyword>
  <keyword>duct</keyword>
  <keyword>biliary</keyword>
  <keyword>malignant</keyword>
  <keyword>obstruction</keyword>
  <keyword>stent</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

